CT antigen immunohistochemistry and mRNA expression in MGUS and multiple myeloma
. | CT7 (MAGE-C1) (%) . | MAGE-A (%) . | NY-ESO-1 (%) . |
|---|---|---|---|
| MGUS | |||
| RT-PCR, n = 6 | 1/6 (17) | 5/6 (83) | 0/5 (0) |
| IHC, n = 15 | 2/15 (13)* | 6/15 (40)† | 0/15 (0) |
| Stage I/II | |||
| RT-PCR, n = 3 | 2/3 (67) | 1/3 (33) | 1/3 (33) |
| IHC, n = 4 | 3/4 (75) | 2/4 (50) | 1/4 (25) |
| Stage III | |||
| RT-PCR, n = 7 | 6/7 (86) | 7/7 (100) | 1/5 (20) |
| IHC, n = 33 | 27/33 (82)* | 23/33 (70)† | 7/33 (21) |
. | CT7 (MAGE-C1) (%) . | MAGE-A (%) . | NY-ESO-1 (%) . |
|---|---|---|---|
| MGUS | |||
| RT-PCR, n = 6 | 1/6 (17) | 5/6 (83) | 0/5 (0) |
| IHC, n = 15 | 2/15 (13)* | 6/15 (40)† | 0/15 (0) |
| Stage I/II | |||
| RT-PCR, n = 3 | 2/3 (67) | 1/3 (33) | 1/3 (33) |
| IHC, n = 4 | 3/4 (75) | 2/4 (50) | 1/4 (25) |
| Stage III | |||
| RT-PCR, n = 7 | 6/7 (86) | 7/7 (100) | 1/5 (20) |
| IHC, n = 33 | 27/33 (82)* | 23/33 (70)† | 7/33 (21) |
CT7 and MAGE-A family mRNA and protein are commonly detected in stage-III multiple myeloma.
There is a 69% difference in the fraction of CT7-positive specimens between MGUS and stage-III myeloma (P < .001, 95% confidence interval 43%-95%).
There is a 30% difference of expression in MAGE-A3/6 expression between MGUS and stage-III myeloma (P < .1).